<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="age assessed in acute hospitals in the UK with clinical" exact="diagnosis" post="of COVID-19 infection where management on an ambulatory care"/>
 <result pre="acute hospitals in the UK with clinical diagnosis of COVID-19" exact="infection" post="where management on an ambulatory care pathway is deemed"/>
 <result pre="of MERS-CoV [1], and azithromycin has been tried in COVID-19" exact="infection" post="[2] although RCT data for any coronavirus disease are"/>
 <result pre="AZMâ€™s anti-inflammatory propertiesâ€&quot;rather than antiviralâ€&quot;will be more important in the" exact="treatment" post="of severe COVID-19 disease in secondary care. Antivirals are"/>
 <result pre="of gram-positive, gram-negative, anaerobic and atypical infections may reduce secondary" exact="infection" post="which were found in 16% of COVID-19 deaths [23]."/>
 <result pre="for 14â€‰days, similar to the dose recommended in UK for" exact="treatment" post="of Lyme disease [47]. This dose is selected to"/>
 <result pre="support or death in adult patients with clinically diagnosed COVID-19" exact="infection" post="being assessed in secondary care but initially managed on"/>
 <result pre="compare the effect of azithromycin in participants with a clinical" exact="diagnosis" post="of COVID-19 in reducing the proportion with either death"/>
 <result pre="compare the effect of azithromycin in participants with a PCR-confirmed" exact="diagnosis" post="of COVID-19 in reducing the proportion with either death"/>
 <result pre="theoretical grounds [48] and on data from in vitro drug" exact="screening" post="[12] of molecules which could be repositioned. This approach"/>
 <result pre="extremely useful drug for a wide variety of indications including" exact="treatment" post="or prevention of a range of bacterial infections of"/>
 <result pre="response and also insight into the immune consequences of SARS-CoV-2" exact="infection" post="on the peripheral blood and airway epithelial cell transcriptome."/>
 <result pre="are grateful to the Nankai University for provision of PCR" exact="testing" post="kits. Authorsâ€™ contributions TSCH, VSB, JB, SJD, MJ, JM,"/>
 <result pre="SyndromeInt J Infect Dis20198118419030690213 2.GautretPLagierJParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
 <result pre="Respir Crit Care Med19961543 Pt 16546608810601 10.AndreaniJLe BideauMDuflotIJardotPRollandCBoxbergerMet al.In vitro" exact="testing" post="of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic"/>
 <result pre="A, Decroly E, de Lamballerie X, et al. In vitro" exact="screening" post="of a FDA approved chemical library reveals potential inhibitors"/>
 <result pre="K, Quanquin N, et al. Azithromycin protects against Zika virus" exact="infection" post="by upregulating virus-induced type I and III interferon responses."/>
 <result pre="centerInt J Antimicrob Agents201851691892429501821 19.LeeNWongCKChanMCWYeungESLTamWWSTsangOTYet al.Anti-inflammatory effects of adjunctive macrolide" exact="treatment" post="in adults hospitalized with influenza: a randomized controlled trialAntivir"/>
 <result pre="in severe acute respiratory syndromeClin Exp Immunol200413619510315030519 28.MahallawiWHcollab: Khabour OFZhangQMakhdoumHMSulimanBAMERS-CoV" exact="infection" post="in humans is associated with a pro-inflammatory Th1 and"/>
</results>
